Anxiety and Addiction: Dual Diagnosis Treatment

Anxiety and addiction is the clinical pattern of a person living with both an anxiety disorder and a substance use disorder (SUD) at the same time, also called a co-occurring disorder or dual diagnosis. According to the National Institute on Drug Abuse, anxiety disorders are among the most common psychiatric conditions paired with SUD, and integrated treatment, addressing both conditions simultaneously, is the standard of care (NIDA, 2024). The pattern is bidirectional: anxiety often drives substance use as self-medication, and chronic substance use worsens anxiety over time.

This guide explains how anxiety and addiction interact, how clinicians distinguish a substance-induced anxiety disorder from an independent one, and what evidence-based treatment looks like in 2026, including the therapies, medications, and levels of care that actually move the needle. It is written for people considering treatment for themselves, for family members trying to understand the dual presentation, and for clinicians cross-referencing options. Dr. Richard Marasa, Medical Director of Clear Steps Recovery, reviewed the clinical claims below.

What is the connection between anxiety and addiction?

The connection between anxiety and addiction is bidirectional, meaning each condition can cause, worsen, or maintain the other. The dominant clinical model is the self-medication hypothesis: people with untreated anxiety disorders use alcohol, benzodiazepines, cannabis, or opioids to blunt symptoms the nervous system cannot quiet on its own (Khantzian, originally 1985, refined in subsequent NIDA-funded research). Short-term relief is real, which is why the pattern forms. The long-term cost is consistent across substances. The brain adapts, tolerance builds, sleep and mood deteriorate, and withdrawal-related anxiety stacks on top of the original disorder.

A second mechanism runs in the opposite direction. Heavy substance use sensitizes the same stress and reward pathways that anxiety dysregulates, so people often feel more anxious in early abstinence before they feel better. The American Psychiatric Association's DSM-5-TR formally recognizes substance-induced anxiety disorder as a separate diagnosis, distinct from an independent anxiety disorder, when symptoms develop during or shortly after substance use or withdrawal (APA, 2022). The clinical implication is straightforward. Treating only the addiction leaves the anxiety driver in place, and treating only the anxiety while substance use continues blocks most of the available tools from working.

Why the bidirectional model matters for treatment

If you treat anxiety and addiction sequentially, asking the patient to get sober first and address anxiety later, you typically produce one of two results: relapse driven by untreated anxiety, or partial sobriety with continued anxiety symptoms that erode quality of life and motivation. Multiple randomized trials and SAMHSA's Treatment Improvement Protocol 42 establish integrated treatment as the standard of care for this exact reason (SAMHSA, TIP 42, 2020 update).

How common is co-occurring anxiety and SUD?

Co-occurring anxiety and substance use disorder is one of the most common dual presentations in U.S. adult mental health. According to the National Epidemiologic Survey on Alcohol and Related Conditions III (NESARC-III), 17.7% of U.S. adults with a 12-month alcohol use disorder also met criteria for an anxiety disorder in the same year, and lifetime rates run higher (Grant et al., JAMA Psychiatry, 2015). For people with generalized anxiety disorder specifically, NESARC-III data show 45.9% also meet lifetime criteria for alcohol use disorder, 14.3% for cannabis use disorder, and 44.6% for tobacco use disorder. SAMHSA's 2023 National Survey on Drug Use and Health reports 21.5 million U.S. adults with a co-occurring mental illness and substance use disorder, with anxiety disorders among the most frequently represented diagnoses.

Clinical samples skew higher than general-population samples. In specialty SUD treatment settings, roughly 30 to 40 percent of patients screen positive for an anxiety disorder, depending on substance and population (Journal of Substance Abuse Treatment reviews). Despite the prevalence, most adults with co-occurring conditions do not receive treatment for both, and many receive treatment for neither. This is the gap integrated treatment is designed to close.

Which anxiety disorders most often co-occur with substance use?

The DSM-5-TR groups several distinct disorders under the anxiety umbrella, and each shows a different pattern of substance comorbidity. The five most clinically relevant for SUD are generalized anxiety disorder (GAD), panic disorder, social anxiety disorder (SAD), agoraphobia, and specific phobia. Substance-induced anxiety disorder, defined by symptoms occurring during intoxication or withdrawal, is a sixth category that often complicates assessment in early treatment. Each disorder has a typical substance pairing that clinicians watch for.

Generalized anxiety disorder, marked by persistent worry across multiple domains, pairs most often with alcohol and cannabis, both of which transiently quiet rumination. Panic disorder, which produces discrete intense surges of fear with cardiovascular symptoms, pairs with alcohol and benzodiazepines because both rapidly reduce acute autonomic arousal. Social anxiety disorder pairs heavily with alcohol; people with SAD describe alcohol as the medication that lets them enter social situations, and NESARC data show especially elevated AUD rates in this population. Agoraphobia and specific phobia show smaller but still meaningful associations, often through avoidance behavior that constrains the person's life and increases vulnerability to substance use as a coping tool.

Common substance pairings clinicians see

Alcohol is the single most common substance paired with anxiety disorders, followed by cannabis, benzodiazepines, nicotine, and opioids. Stimulants like cocaine and methamphetamine usually worsen anxiety acutely, but a subset of patients with attention or arousal regulation problems still use them to function, then experience rebound anxiety as the stimulant wears off. Opioid use disorder pairs with anxiety in a more complex way. Opioids reduce emotional pain in the short term, but withdrawal produces severe anxiety that often drives continued use. The pattern matters because the right medication and therapy plan depends on which substances and which anxiety disorder are present.

Substance-induced anxiety vs. an independent anxiety disorder

Distinguishing a substance-induced anxiety disorder from an independent anxiety disorder is one of the most important assessment tasks in dual diagnosis. The DSM-5-TR defines substance-induced anxiety disorder as anxiety symptoms that develop during or within one month of intoxication or withdrawal from a substance known to produce them, where the symptoms are clinically significant and not better explained by a pre-existing disorder (APA, 2022). Stimulants, alcohol withdrawal, cannabis, hallucinogens, and benzodiazepine withdrawal all commonly produce substance-induced anxiety. Caffeine intoxication is also recognized in DSM-5-TR.

In practice, clinicians often defer a definitive anxiety diagnosis until the patient has been free of acute intoxication and withdrawal for two to four weeks. This is not a delay in care, it is a clinical reality. Symptoms during early abstinence frequently resemble GAD or panic disorder but resolve as the nervous system stabilizes. If symptoms persist past the stabilization window, an independent anxiety disorder is more likely, and the treatment plan adjusts accordingly. The National Institute of Mental Health and SAMHSA both endorse this staged-assessment approach for accurate diagnosis (NIMH, 2024; SAMHSA TIP 42, 2020).

Why this distinction shapes the treatment plan

If anxiety is substance-induced and resolves with abstinence, the core treatment is the SUD work itself. If anxiety is an independent disorder, integrated treatment must include direct anxiety care, which usually means cognitive-behavioral therapy with or without an SSRI. Skipping this assessment step is a leading cause of treatment failure in dual diagnosis. Patients diagnosed too early often end up on medications they do not need, while patients dismissed as "just withdrawal" walk out of treatment with an unaddressed disorder still driving their use.

How is dual diagnosis treated? Integrated vs sequential vs parallel

There are three historical models for treating co-occurring anxiety and SUD, and only one is the current standard of care. Sequential treatment treats one disorder first, then the other, usually addiction first and anxiety later. Parallel treatment addresses both disorders simultaneously, but in different settings, often by different teams who do not coordinate. Integrated treatment addresses both disorders simultaneously, in the same setting, by a single coordinated clinical team. SAMHSA's Treatment Improvement Protocol 42 establishes integrated treatment as the preferred model for co-occurring disorders, based on more than two decades of research (SAMHSA, TIP 42, 2020 update).

The advantage is mechanical. Anxiety often drives the substance use that interferes with anxiety treatment, and substance use produces anxiety that interferes with SUD treatment. When the same team treats both, with shared assessment, shared treatment goals, and shared crisis planning, the conditions stop reinforcing each other inside the treatment plan itself. NIMH and the National Institute on Drug Abuse both recommend integrated treatment as the first-line approach for any patient presenting with co-occurring mental illness and SUD (NIMH, 2024; NIDA, 2024).

What integrated treatment actually looks like day to day

A patient with co-occurring GAD and alcohol use disorder might attend a relapse-prevention group on Monday, a CBT-for-anxiety individual session on Wednesday, a medication-management visit on Friday, and a family session every other week, with all clinicians sharing notes and pulling in the same direction. The schedule is built so that stabilization comes first, the anxiety work begins as soon as the patient can engage, and long-term recovery skills get reinforced throughout. It is less about a specific program label and more about a disciplined refusal to split the person into two separate problems.

Therapies that work for both anxiety and SUD

Several evidence-based psychotherapies have been studied or adapted for co-occurring anxiety and substance use disorder. The strongest support is for cognitive-behavioral therapy (CBT), motivational interviewing (MI), mindfulness-based relapse prevention, acceptance and commitment therapy (ACT), and integrated CBT protocols designed specifically for AUD plus anxiety. The American Psychological Association lists CBT as a first-line treatment for both anxiety disorders and SUD, and integrated CBT protocols have shown reductions in both anxiety symptoms and drinking in randomized trials at Stanford, Brown, and the VA system (APA, 2024; Kushner et al., Journal of Substance Abuse Treatment).

CBT for anxiety teaches patients to identify the cognitive patterns that fuel worry, panic, or avoidance, and to test those patterns against reality through gradual exposure and behavioral experiments. CBT for SUD teaches patients to identify high-risk situations, develop coping strategies, and rehearse responses before cravings hit. Integrated protocols combine both, so a single session might address a panic-symptom cognition ("my heart is racing, I'm having a heart attack") and the substance-use response that follows ("I need a drink to calm down"). Exposure therapy is used cautiously in early recovery because activating exposure can destabilize a patient still managing acute cravings, but it is highly effective once stabilization is in place.

Mindfulness, ACT, and motivational interviewing

Mindfulness-based relapse prevention (MBRP), developed at the University of Washington, teaches patients to observe craving and anxiety as transient mental events without acting on them. Acceptance and commitment therapy (ACT) helps patients pursue values-based behavior even in the presence of difficult internal experiences, which is well-suited to chronic anxiety. Motivational interviewing is the communication style underlying most modern dual-diagnosis treatment. It is non-confrontational and elicits the patient's own reasons for change, which matters because confrontation often increases anxiety and reinforces the substance use it tries to reduce. Most outpatient programs, including Clear Steps Recovery, use MI as the foundation and layer CBT, MBRP, or ACT on top depending on the clinical picture.

Medication considerations

Medication plays a supporting role in dual-diagnosis treatment, and prescribing decisions are individualized by a licensed prescriber who knows both the psychiatric and substance-use history. For independent anxiety disorders in patients with co-occurring SUD, SSRIs and SNRIs are generally considered first-line because they treat anxiety effectively and have low abuse liability. Sertraline, paroxetine, escitalopram, and venlafaxine all have FDA-approved indications for one or more anxiety disorders. Buspirone, a non-benzodiazepine anxiolytic, has shown benefit for patients with GAD and co-occurring AUD, with one randomized trial finding greater anxiety reduction, slower return to drinking, and improved retention compared with placebo (Kranzler et al., Journal of Substance Abuse Treatment).

Benzodiazepines, including alprazolam, lorazepam, clonazepam, and diazepam, are FDA-approved for anxiety disorders and are highly effective in the short term. They also carry significant abuse liability, especially in patients with a history of any substance use disorder. The American Society of Addiction Medicine and most clinical guidelines recommend against routine long-term benzodiazepine use in patients with co-occurring SUD, reserving them for short-term, medically supervised situations such as alcohol withdrawal management. This is not a moral judgment about benzodiazepines, which are appropriate medications in many clinical contexts. It is a practical assessment of risk in this specific population.

Important safety note on benzodiazepine and alcohol cessation

Abrupt cessation of benzodiazepines or heavy alcohol use can be dangerous and, in severe cases, fatal. Withdrawal from either substance can produce seizures, delirium, and life-threatening autonomic instability. If you are using benzodiazepines daily or drinking heavily on a regular basis, do not stop abruptly. Medically supervised tapering, in an outpatient or inpatient setting depending on severity, is the safe approach. A qualified prescriber will assess your risk and develop a tapering plan that protects you while moving toward recovery.

Other medications used in dual diagnosis

For alcohol use disorder, three medications have FDA approval: naltrexone (oral or monthly injection), acamprosate, and disulfiram. Gabapentin and topiramate have off-label evidence for AUD and are sometimes used when first-line options are not tolerated. Gabapentin in particular has shown some benefit for AUD with prominent anxiety symptoms, though abuse potential exists and prescribing is individualized. For opioid use disorder, buprenorphine and methadone are gold-standard medications, with naltrexone as a third option. Any medication for co-occurring anxiety and SUD should be prescribed by a clinician who has the full picture, not added piecemeal.

Finding the right level of care

Dual-diagnosis treatment is delivered across a continuum of care, and matching level of care to clinical severity is a core ASAM principle. Standard outpatient (one to two sessions per week) is appropriate for stable patients with mild-to-moderate anxiety and SUD who have a stable home environment. Intensive outpatient (IOP), typically nine or more clinical hours per week, suits patients who need more structure, recent withdrawal stabilization, or multiple weekly therapy contacts. Partial hospitalization (PHP), at 20 or more clinical hours per week, is for patients who need near-daily structure but not 24-hour supervision. Residential and inpatient treatment is appropriate for severe presentations, complex medical needs, or patients without a safe environment for outpatient work.

Clear Steps Recovery offers integrated dual-diagnosis care at the outpatient and intensive outpatient levels in New Hampshire (Londonderry) and at the Evening Treatment level in Massachusetts (Needham). Both programs include CBT, motivational interviewing, medication management, family sessions, and care coordination with prescribers and primary care. Patients who need a higher level of care than CSR offers are referred to partner programs for stabilization and welcomed back for ongoing outpatient work. The right starting level is best determined by a clinical assessment, not by self-diagnosis.

Crisis resources you should keep on hand

People with co-occurring anxiety and substance use disorder face elevated suicide risk, particularly during early abstinence and acute symptom flares. Two free, confidential, 24/7 resources should be in every patient's and family's contact list. The 988 Suicide & Crisis Lifeline (call or text 988) connects to trained counselors who can de-escalate a crisis and help with next steps. SAMHSA's National Helpline (1-800-662-HELP / 4357) provides treatment referrals in English and Spanish. If you or someone you love is in immediate danger, call 911. Naloxone, available without prescription at most pharmacies, should be on hand for anyone with an opioid use history.

Taking the next step

If you recognize yourself or someone you love in this guide, the next step is usually small. A confidential phone conversation with a clinician can clarify what level of care fits your actual situation, what your insurance covers, and what an integrated dual-diagnosis assessment looks like. There is no obligation, and no one is admitted against their will. Family members can call for information without the patient present.

Clear Steps Recovery offers integrated outpatient dual-diagnosis treatment for adults with co-occurring anxiety and substance use disorder at our Londonderry, New Hampshire and Needham, Massachusetts locations. Call (603) 769-8981 (NH) or (781) 765-0001 (MA) for a confidential assessment. Our admissions team is available 24/7. To learn more about our clinical approach, read about Dr. Marasa's background or explore related resources on PTSD and addiction and the stages of change in recovery.

If you are in crisis, call or text 988 (Suicide & Crisis Lifeline) or SAMHSA's National Helpline at 1-800-662-HELP (4357), available 24/7 and confidential.